Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:26359368  

NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.

Maria E R Garcia-Rendueles | Julio C Ricarte-Filho | Brian R Untch | Iňigo Landa | Jeffrey A Knauf | Francesca Voza | Vicki E Smith | Ian Ganly | Barry S Taylor | Yogindra Persaud | Gisele Oler | Yuqiang Fang | Suresh C Jhanwar | Agnes Viale | Adriana Heguy | Kety H Huberman | Filippo Giancotti | Ronald Ghossein | James A Fagin
Cancer discovery | 2015

Ch22q LOH is preferentially associated with RAS mutations in papillary and in poorly differentiated thyroid cancer (PDTC). The 22q tumor suppressor NF2, encoding merlin, is implicated in this interaction because of its frequent loss of function in human thyroid cancer cell lines. Nf2 deletion or Hras mutation is insufficient for transformation, whereas their combined disruption leads to murine PDTC with increased MAPK signaling. Merlin loss induces RAS signaling in part through inactivation of Hippo, which activates a YAP-TEAD transcriptional program. We find that the three RAS genes are themselves YAP-TEAD1 transcriptional targets, providing a novel mechanism of promotion of RAS-induced tumorigenesis. Moreover, pharmacologic disruption of YAP-TEAD with verteporfin blocks RAS transcription and signaling and inhibits cell growth. The increased MAPK output generated by NF2 loss in RAS-mutant cancers may inform therapeutic strategies, as it generates greater dependency on the MAPK pathway for viability.

Pubmed ID: 26359368

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

  • Agency: NCI NIH HHS, United States
    Id: T32 CA160001
  • Agency: NCI NIH HHS, United States
    Id: R01 CA072597
  • Agency: NCI NIH HHS, United States
    Id: R01 CA050706
  • Agency: NCI NIH HHS, United States
    Id: CA72597
  • Agency: NCI NIH HHS, United States
    Id: P50 CA172012
  • Agency: NCI NIH HHS, United States
    Id: P30 CA008748
  • Agency: NCI NIH HHS, United States
    Id: P30-CA008748
  • Agency: NCI NIH HHS, United States
    Id: CA50706
  • Agency: NCI NIH HHS, United States
    Id: P50-CA72012

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.